These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 8629630)

  • 1. A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin.
    Bernardini J; Piraino B; Holley J; Johnston JR; Lutes R
    Am J Kidney Dis; 1996 May; 27(5):695-700. PubMed ID: 8629630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of preventing Staphylococcus aureus carriage on rates of peritoneal catheter-related staphylococcal infections. Literature synthesis.
    Ritzau J; Hoffman RM; Tzamaloukas AH
    Perit Dial Int; 2001; 21(5):471-9. PubMed ID: 11757831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decrease in Staphylococcus aureus exit-site infections and peritonitis in CAPD patients by local application of mupirocin ointment at the catheter exit site.
    Thodis E; Bhaskaran S; Pasadakis P; Bargman JM; Vas SI; Oreopoulos DG
    Perit Dial Int; 1998; 18(3):261-70. PubMed ID: 9663889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effectiveness of mupirocin preventing Staphylococcus aureus in catheter-related infections in peritoneal dialysis.
    Thodis E; Passadakis P; Panagoutsos S; Bacharaki D; Euthimiadou A; Vargemezis V
    Adv Perit Dial; 2000; 16():257-61. PubMed ID: 11045306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is it possible to decrease the rate of Staphylococcus aureus peritonitis?
    Piraino B
    Perit Dial Int; 1996; 16(5):446-7. PubMed ID: 8914174
    [No Abstract]   [Full Text] [Related]  

  • 6. Prophylaxis against gram-positive organisms causing exit-site infection and peritonitis in continuous ambulatory peritoneal dialysis patients by applying mupirocin ointment at the catheter exit site.
    Wong SS; Chu KH; Cheuk A; Tsang WK; Fung SK; Chan HW; Tong MK
    Perit Dial Int; 2003 Dec; 23 Suppl 2():S153-8. PubMed ID: 17986538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nasal mupirocin prevents Staphylococcus aureus exit-site infection during peritoneal dialysis. Mupirocin Study Group.
    J Am Soc Nephrol; 1996 Nov; 7(11):2403-8. PubMed ID: 8959632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of peritoneal dialysis catheter infections in Saudi peritoneal dialysis patients: the emergence of high-level mupirocin resistance.
    Al-Hwiesh AK; Abdul-Rahman IS; Al-Muhanna FA; Al-Sulaiman MH; Al-Jondebi MS; Divino-Filho JC
    Int J Artif Organs; 2013 Jul; 36(7):473-83. PubMed ID: 23897229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of once- or thrice-weekly mupirocin application on mupirocin resistance in patients on continuous ambulatory peritoneal dialysis--first 6 months' experience.
    Cavdar C; Zeybel M; Atay T; Sifil A; Sanlidag C; Gulay Z; Camsari T
    Adv Perit Dial; 2004; 20():62-6. PubMed ID: 15384797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, double-blind trial of antibiotic exit site cream for prevention of exit site infection in peritoneal dialysis patients.
    Bernardini J; Bender F; Florio T; Sloand J; Palmmontalbano L; Fried L; Piraino B
    J Am Soc Nephrol; 2005 Feb; 16(2):539-45. PubMed ID: 15625071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "Pulse" nasal mupirocin maintenance regimen in patients undergoing continuous ambulatory peritoneal dialysis.
    Mylotte JM; Kahler L; Jackson E
    Infect Control Hosp Epidemiol; 1999 Nov; 20(11):741-5. PubMed ID: 10580624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome and clinical implications of a surveillance and treatment program for Staphylococcus aureus nasal carriage in peritoneal dialysis patients.
    Crabtree JH; Hadnott LL; Burchette RJ; Siddiqi RA
    Adv Perit Dial; 2000; 16():271-5. PubMed ID: 11045309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decrease in infections with the introduction of mupirocin cream at the peritoneal dialysis catheter exit site.
    Uttley L; Vardhan A; Mahajan S; Smart B; Hutchison A; Gokal R
    J Nephrol; 2004; 17(2):242-5. PubMed ID: 15293524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of weekly mupirocin application on infections in continuous ambulatory peritoneal dialysis patients.
    Zeybel M; Ozder A; Sanlidag C; Yildiz S; Cavdar C; Ersoy R; Celik A; Camsari T
    Adv Perit Dial; 2003; 19():198-201. PubMed ID: 14763062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Effectiveness of Local Application of Chlorhexidine Gluconate, Mupirocin Ointment, and Normal Saline for the Prevention of Peritoneal Dialysis-related Infections (COSMO-PD Trial): a multicenter randomized, double-blind, controlled protocol.
    Nochaiwong S; Ruengorn C; Noppakun K; Panyathong S; Dandecha P; Sood MM; Saenjum C; Awiphan R; Sirilun S; Mongkhon P; Chongruksut W; Thavorn K;
    Trials; 2019 Dec; 20(1):754. PubMed ID: 31856900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of once-a-week vs thrice-a-week application of mupirocin on methicillin and mupirocin resistance in peritoneal dialysis patients: three years of experience.
    Cavdar C; Saglam F; Sifil A; Celik A; Atay T; Gungor O; Ozder A; Gulay Z; Camsari T
    Ren Fail; 2008; 30(4):417-22. PubMed ID: 18569916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of catheter related infections in patients on CAPD.
    Thodis E; Passadakis P; Vargemezis V; Oreopoulos DG
    Int J Artif Organs; 2001 Oct; 24(10):671-82. PubMed ID: 11817317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of local mupirocin application on exit-site infection and peritonitis in an Indian peritoneal dialysis population.
    Mahajan S; Tiwari SC; Kalra V; Bhowmik DM; Agarwal SK; Dash SC; Kumar P
    Perit Dial Int; 2005; 25(5):473-7. PubMed ID: 16178481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal mupirocin does not prevent exit-site infections in children receiving peritoneal dialysis.
    Araki Y; Hataya H; Ikeda M; Ishikura K; Honda M
    Perit Dial Int; 2003; 23(3):267-9. PubMed ID: 12938828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized controlled trial of prophylactic rifampin for peritoneal dialysis-related infections.
    Zimmerman SW; Ahrens E; Johnson CA; Craig W; Leggett J; O'Brien M; Oxton L; Roecker EB; Engeseth S
    Am J Kidney Dis; 1991 Aug; 18(2):225-31. PubMed ID: 1867179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.